I undertook my undergraduate medical training at the University of Sheffield, where I completed an intercalated BMedSci degree in pathology in 1995, and qualified in 1998. After completing Basic Surgical Training in South Yorkshire in 2003, I was awarded a Medical Research Council Fellowship (2004-2007) and undertook a PhD researching molecular mechanisms of prostate cancer progression. I then undertook higher surgical training in Urology in both Sheffield and Oxford, whilst in parallel continuing to pursue my prostate cancer research interests, leading to numerous scientific publications in this field under the mentorship of Professor Freddie Hamdy. In 2015, I was appointed Locum Consultant Urologist in Oxford and continued to combine clinical practice, specialising in the diagnosis and management of prostate cancer, with prostate cancer research. In 2017 I was appointed Honorary Consultant Urologist in Oxford.
Cancer Research UK / Royal College of Surgeons of England Clinician Scientist Fellow
- Honorary Urology Consultant
I am a Cancer Research UK Clinician Scientist Fellow (joint with the Royal College of Surgeons of England), which enables me to continue to combine my care of prostate cancer patients with a wide and growing prostate cancer research portfolio, covering the breadth of basic science, translational, and clinical research, at the Nuffield Department of Surgical Sciences.
I have been the Lead Clinician for the VANCE (VAcciNation in prostate CancEr) Clinical trial in Oxford since 2015, and in 2017 I commenced my current position as Honorary Consultant Urologist at the Churchill Hospital in Oxford.
I also deliver undergraduate teaching in surgery and urology to clinical medical students.
- Executive committee member of the Academic Section of the British Association of Urological Surgeons (BAUS) (2017-2019)
- Full member of BAUS, the European Urology Association (EAU), and the American Urology Association (AUA)
Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?
Bryant RJ. et al, (2018), BJU Int
Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients.
Gonnissen A. et al, (2018), Am J Pathol, 188, 795 - 804
Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.
Hamdy FC. et al, (2017), Eur Urol
IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer.
Aleksic T. et al, (2017), Br J Cancer, 117, 1600 - 1606
Orient Expression: Solving the Mystery of Asian Prostate Cancer?
Lamb AD. et al, (2017), Eur Urol